热门资讯> 正文
通用会计准则每股收益为-1.70美元
2025-10-30 19:29
- Nuvalent press release (NUVL): Q3 GAAP EPS of -$1.70.
- Cash, cash equivalents and marketable securities were $943.1 million as of September 30, 2025. Nuvalent continues to believe its existing cash, cash equivalents and marketable securities will be sufficient to fund its current operating plan into 2028.
- R&D Expenses: Research and development (R&D) expenses were $83.8 million for the third quarter of 2025.
- G&A Expenses: General and administrative (G&A) expenses were $28.9 million for the third quarter of 2025.
- Net Loss: Net loss was $122.4 million for the third quarter of 2025.
More on Nuvalent
- Nuvalent, Inc. (NUVL) Presents at UBS Virtual Oncology Day Transcript
- Piper Sandler initiates coverage of oncology companies
- Seeking Alpha’s Quant Rating on Nuvalent
- Historical earnings data for Nuvalent
- Financial information for Nuvalent
推荐文章
美股机会日报 | 大摩警告！若薪酬方案被否，特斯拉或跌超10％；微软获批向阿联酋出口最新款英伟达芯片
美债上演大反攻 “Sell America”大错特错! 嘴上喊“美国例外论坍塌”的机构实际上狂买美债?
华盛早报 | 美政府“停摆”逼近历史记录！巴菲特卸任前最后财报：伯克希尔3817亿美元现金储备创新高，营业利润激增34%；美股今起进入冬令时
明略科技-W今日上市：香港公开发售获4452.86倍认购
新能源汽车“银十”热销 多家车企交付量破纪录
英伟达市值突破 5 万亿：回顾它与加密货币的曾经蜜月期
“股神”巴菲特旗下伯克希尔财报出炉，现金储备超3800亿美元创历史记录！速看前五大持仓
港股周报 | 中美经贸磋商成果：取消10%关税、暂停对等关税！恒指三连跌失守26000点关口
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
